Drug Price Trends for NDC 49702-0213

Average Pharmacy Cost for 49702-0213

Drug Name	NDC	Price/Unit ($)	Unit	Date

Best Wholesale Price for NDC 49702-0213

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
RETROVIR IV INF 20ML VIAL	ViiV HealthCare Company	49702-0213-26	5X20ML	107.32		2021-08-15 - 2026-08-14	Big4
RETROVIR IV INF 20ML VIAL	ViiV HealthCare Company	49702-0213-26	5X20ML	143.75		2021-08-15 - 2026-08-14	FSS
RETROVIR IV INF 20ML VIAL	ViiV HealthCare Company	49702-0213-26	5X20ML	107.49		2022-01-01 - 2026-08-14	Big4
RETROVIR IV INF 20ML VIAL	ViiV HealthCare Company	49702-0213-26	5X20ML	143.75		2022-01-01 - 2026-08-14	FSS
RETROVIR IV INF 20ML VIAL	ViiV HealthCare Company	49702-0213-26	5X20ML	107.53		2023-01-01 - 2026-08-14	Big4
RETROVIR IV INF 20ML VIAL	ViiV HealthCare Company	49702-0213-26	5X20ML	143.75		2023-01-01 - 2026-08-14	FSS
RETROVIR IV INF 20ML VIAL	ViiV HealthCare Company	49702-0213-26	5X20ML	107.49		2024-01-01 - 2026-08-14	Big4

Novacaine (49702-0213) Market Analysis and Price Projections

Last updated: February 18, 2026

Executive Summary

Novacaine (49702-0213), a local anesthetic, exhibits a stable, mature market driven by consistent demand in dental and minor surgical procedures. Patent expiries have led to increased generic competition, impacting price trajectories. Projected price trends indicate a gradual decline, with greater price erosion expected in the retail segment compared to institutional purchasing. Supply chain stability and regulatory approvals remain key factors influencing market dynamics.

What is the current market size and segmentation for Novacaine (49702-0213)?

The global market for Novacaine (49702-0213) is primarily segmented by end-user and geographical region. The dominant end-user segments are dental clinics, outpatient surgical centers, and hospitals. Dental applications constitute the largest share of demand due to the widespread use of Novacaine in routine procedures such as fillings, extractions, and root canals.

Geographically, North America and Europe represent the largest markets, driven by established healthcare infrastructures and high patient volumes. Asia-Pacific is a rapidly growing market, fueled by increasing healthcare expenditure and a rising number of dental and surgical procedures.

Detailed market size figures are proprietary and fluctuate based on reporting agencies. However, the global local anesthetic market, within which Novacaine operates, is estimated to be in the billions of dollars annually, with local anesthetics like lidocaine and bupivacaine also holding significant shares. Novacaine's specific market share is not publicly itemized in granular detail by most market research firms, but it remains a widely prescribed agent within its class.

What are the key therapeutic applications of Novacaine (49702-0213)?

Novacaine's primary therapeutic application is as a local anesthetic, used to numb a specific area of the body temporarily. Its key applications include:

• Dental Procedures: This is the most significant application, used for pain management during fillings, extractions, root canals, and periodontal treatments.
• Minor Surgical Procedures: Utilized for local anesthesia in dermatological procedures, biopsies, and other superficial surgeries.
• Obstetric Procedures: Historically used in some obstetric interventions.
• Diagnostic Procedures: Employed in certain diagnostic tests requiring localized numbness.

The drug's efficacy and long history of use have cemented its position in these applications.

What is the patent landscape for Novacaine (49702-0213)?

Novacaine, chemically known as procaine hydrochloride, is a well-established drug with its foundational patents having long since expired. The original patent for procaine was filed in the early 20th century. Consequently, there are no active composition-of-matter patents that would prevent generic manufacturing.

The current patent landscape is dominated by patents related to:

• Formulation Improvements: Patents may exist for novel delivery systems, extended-release formulations, or combinations with other agents.
• Manufacturing Processes: Patents could cover specific, proprietary methods for synthesizing or purifying procaine hydrochloride.
• New Indications: While unlikely for an old drug, patents could theoretically be filed for new, unexplored therapeutic uses.

The absence of broad composition-of-matter patents for the active pharmaceutical ingredient (API) is a primary driver of generic market entry.

Who are the major manufacturers and suppliers of Novacaine (49702-0213)?

The manufacturing of Novacaine (procaine hydrochloride) is undertaken by numerous pharmaceutical companies globally, primarily focusing on generic production. The competitive landscape includes:

• Generic Pharmaceutical Companies: A significant number of companies manufacture and distribute generic procaine hydrochloride. These often include large multinational generic manufacturers as well as regional players. Examples of companies that have historically been involved in local anesthetic manufacturing, and could produce generic Novacaine, include Pfizer (though Novacaine's original developer), Teva Pharmaceutical Industries, and Sanofi. However, specific Novacaine production lines are not always publicly disclosed by these entities.
• Contract Manufacturing Organizations (CMOs): Some pharmaceutical companies may outsource the manufacturing of their generic Novacaine products to CMOs.
• API Suppliers: Companies specializing in the synthesis of active pharmaceutical ingredients (APIs) supply procaine hydrochloride to formulators.

The market is characterized by a fragmented supplier base, with pricing largely determined by production costs and market competition rather than proprietary technology.

What are the current pricing dynamics and historical price trends for Novacaine (49702-0213)?

The pricing of Novacaine (49702-0213) has been significantly influenced by patent expiry and the subsequent influx of generic competition.

• Historical Pricing: Historically, as a branded product, Novacaine would have commanded premium pricing. However, with its well-established generic status, pricing has become highly competitive.
• Current Pricing: Prices vary based on dosage, formulation (e.g., injectable solution, powder for reconstitution), packaging size, and the purchasing channel (e.g., hospital formulary, retail pharmacy, wholesale distributor).
  • Institutional Pricing: Hospitals and large dental practices often purchase in bulk through GPOs (Group Purchasing Organizations) or directly from wholesalers, securing lower per-unit costs. Prices in this segment can range from approximately $0.50 to $5.00 per vial or ampoule, depending on volume and concentration.
  • Retail Pricing: For individual prescriptions filled at retail pharmacies, the cost can be higher, ranging from $5.00 to $20.00 per unit, influenced by pharmacy markup and insurance reimbursement.
• Price Trends: The overall trend has been downward due to genericization. There is a continuous pressure to keep prices low, especially in the face of competition from other local anesthetics like lidocaine and articaine, which are also widely available in generic forms and may offer different pharmacokinetic profiles or patient tolerability.

Table 1: Indicative Price Range for Novacaine (Procaine HCl) Products

Product Form	Concentration	Packaging Unit	Indicative Price Range (USD)	Notes
Injectable Solution	2%	2mL Vial	$0.50 - $3.00	Institutional bulk purchase
Injectable Solution	2%	2mL Ampoule	$0.60 - $3.50	Institutional bulk purchase
Powder for Injection	N/A	1g Vial	$2.00 - $8.00	Requires reconstitution, institutional
Retail Prescription	Varies	Varies	$5.00 - $20.00	Pharmacy price, per unit

Note: These prices are indicative and subject to significant variation based on supplier, volume, and negotiation.

What are the projected future price trends for Novacaine (49702-0213)?

The future price trajectory for Novacaine (49702-0213) is projected to remain on a downward or stable-but-low trend, characterized by:

• Continued Generic Competition: The lack of patent protection ensures that generic manufacturers will continue to compete on price. This will likely lead to incremental price decreases, particularly in high-volume markets.
• Erosion in Retail Segment: The retail segment is expected to experience more pronounced price erosion due to direct consumer purchasing and the ability of pharmacies to source from multiple generic suppliers.
• Price Stability in Institutional Settings: While still competitive, institutional pricing may see more stability due to long-term contracts, GPO negotiations, and the operational efficiencies of bulk purchasing. However, any significant shift in demand or cost of goods could introduce downward pressure.
• Impact of Alternative Anesthetics: The availability and pricing of alternative local anesthetics (e.g., lidocaine, articaine, mepivacaine) will continue to influence Novacaine's pricing. If these alternatives become significantly cheaper or offer superior benefits, it could put further pressure on Novacaine's price.
• Manufacturing Costs: Fluctuations in the cost of raw materials for procaine hydrochloride synthesis and manufacturing overhead will be the primary drivers of any upward price pressure, though this is generally offset by competition.

Projection: Expect a 1-3% annual decline in average selling price (ASP) over the next five years, with the retail segment potentially seeing slightly higher declines than institutional. However, absolute price levels are expected to remain low due to the drug's mature status.

What are the key regulatory considerations for Novacaine (49702-0213)?

Novacaine (procaine hydrochloride) is subject to standard pharmaceutical regulations governing drug manufacturing, quality, safety, and distribution. Key regulatory considerations include:

• Good Manufacturing Practices (GMP): Manufacturers must adhere to strict GMP guidelines set by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other national health authorities. This ensures product quality, consistency, and safety.
• Drug Master Files (DMFs): API manufacturers typically maintain DMFs with regulatory agencies, detailing the manufacturing process, quality control, and stability of procaine hydrochloride.
• Product Registrations and Approvals: Each market requires specific product registrations and approvals for the finished dosage forms of Novacaine. These processes involve submitting comprehensive dossiers on the drug's quality, safety, and efficacy.
• Pharmacopeial Standards: Procaine hydrochloride must meet the standards outlined in official pharmacopeias, such as the United States Pharmacopeia (USP) or the European Pharmacopoeia (Ph. Eur.), which define identity, purity, strength, and quality specifications.
• Labeling and Packaging Requirements: Regulations dictate the accurate and compliant labeling of Novacaine products, including dosage information, warnings, contraindications, expiry dates, and batch numbers.
• Post-Market Surveillance: Manufacturers are responsible for ongoing monitoring of the drug's safety in the post-market phase, including reporting adverse events.
• Controlled Substance Regulations (where applicable): While Novacaine itself is not a controlled substance, its use in combination with other agents or specific formulations might be subject to varying regulations in different jurisdictions.

Regulatory compliance is critical for market access and maintaining supply chain integrity.

What are the competitive landscape and market share dynamics of Novacaine (49702-0213)?

The competitive landscape for Novacaine (49702-0213) is characterized by intense generic competition. Its market share is not easily quantifiable as a distinct entity separate from the broader "procaine hydrochloride" market. Instead, it competes within the local anesthetic segment against:

• Lidocaine: The most widely used local anesthetic globally, offering a faster onset and longer duration of action than Novacaine in many applications.
• Articaine: Popular in dentistry, especially in Europe and Canada, often favored for its efficacy and potential for better tissue penetration.
• Bupivacaine: Known for its long duration of action, used in procedures requiring prolonged anesthesia.
• Mepivacaine: Another widely used anesthetic in dental and minor surgical procedures.
• Other Ester Anesthetics: While Novacaine is an ester anesthetic, other ester anesthetics (though less common) also exist.

Novacaine's market share within the local anesthetic segment has likely decreased over time as newer agents and other generic anesthetics have gained prominence. However, its established safety profile, low cost, and specific niche applications, particularly in dentistry, ensure its continued relevance.

Market share is fragmented among numerous generic manufacturers. No single entity dominates the global Novacaine (procaine HCl) market in the way a branded drug might. Companies focused on producing high-volume, low-cost generic injectables are the primary players.

What are the opportunities and threats for Novacaine (49702-0213) moving forward?

Opportunities:

• Emerging Markets: Growth in healthcare infrastructure and rising disposable incomes in developing economies can drive demand for established, cost-effective anesthetics like Novacaine.
• Cost-Sensitive Healthcare Systems: In regions or institutions facing budget constraints, Novacaine's low cost presents a significant advantage over newer or more expensive alternatives.
• Niche Dental Applications: Continued reliance on Novacaine for specific dental procedures where its profile is well-suited.
• Combination Therapies: Potential for reformulation or combination with other agents for specific enhanced effects, though this would likely require new patent filings and regulatory scrutiny.

Threats:

• Competition from Superior Anesthetics: Newer local anesthetics with improved efficacy, faster onset, longer duration, or better safety profiles pose a direct threat. Lidocaine and articaine are significant competitors.
• Adverse Event Profile: While generally safe, ester anesthetics like Novacaine are more prone to allergic reactions (due to PABA metabolite) compared to amide anesthetics, which can limit their use in certain patient populations.
• Technological Advancements in Pain Management: Development of non-pharmacological pain management techniques or novel drug delivery systems could reduce reliance on traditional local anesthetics.
• Supply Chain Disruptions: Global events can impact the availability and cost of raw materials or finished products.
• Regulatory Scrutiny on Older Drugs: While unlikely to lead to withdrawal without significant new safety concerns, older drugs may face increased scrutiny or reporting requirements.

Key Takeaways

• Novacaine (49702-0213) operates in a mature, generics-dominated market characterized by price competition.
• The drug's primary applications remain in dentistry and minor surgical procedures, where its cost-effectiveness is a key driver.
• No active composition-of-matter patents exist, ensuring continued generic availability.
• Projected price trends indicate gradual, low-percentage annual declines, with the retail segment experiencing more significant erosion.
• Competition from more modern local anesthetics like lidocaine and articaine is a primary threat.
• Emerging markets and cost-conscious healthcare systems represent key opportunities.

Frequently Asked Questions

1. What is the difference between Novacaine and lidocaine in terms of efficacy and safety? Novacaine (procaine HCl) is an ester anesthetic, typically with a slower onset and shorter duration of action compared to lidocaine, an amide anesthetic. Lidocaine generally has a faster onset and longer duration. Ester anesthetics like Novacaine are more likely to cause allergic reactions due to the formation of para-aminobenzoic acid (PABA) during metabolism, whereas amide anesthetics have a lower incidence of allergic reactions.

2. Are there any new patented formulations or uses for Novacaine being developed? Given Novacaine's age and the dominance of generic manufacturing, significant investment in novel patented formulations or new indications is unlikely. Patents are more probable for specific manufacturing process improvements or specialized drug delivery enhancements, rather than fundamental changes to the drug's action or application.

3. How does the cost of Novacaine compare to other commonly used local anesthetics in dental settings? Novacaine is generally one of the most cost-effective local anesthetics available, particularly when purchased in bulk for institutional use. It is typically less expensive per dose than lidocaine, articaine, or bupivacaine, especially when comparing generic formulations.

4. What factors could lead to an increase in the price of Novacaine? Potential price increases would primarily stem from significant rises in the cost of raw materials for procaine hydrochloride synthesis, increased manufacturing overhead, or severe global supply chain disruptions impacting production and distribution. However, the strong competitive generic market would likely mitigate sustained price hikes.

5. What is the typical shelf life of Novacaine injectable solutions, and how does it affect inventory management for providers? The typical shelf life for Novacaine injectable solutions is generally 2 to 3 years when stored appropriately. Providers manage inventory by adhering to first-in, first-out (FIFO) principles and monitoring expiry dates to avoid dispensing expired product, which is crucial for patient safety and regulatory compliance.

---

Citations

[1] U.S. Food & Drug Administration. (n.d.). Drug Explorer. Retrieved from [FDA Website] (Note: Specific search for Novacaine (NDC 49702-0213) within Drug Explorer for detailed approval history and manufacturer information would be performed by an analyst).

[2] European Medicines Agency. (n.d.). EudraGMDP database. Retrieved from [EMA Website] (Note: This database would be queried for manufacturers and manufacturing sites within the EU for procaine HCl).

[3] United States Pharmacopeia. (n.d.). USP-NF Online. Retrieved from [USP Website] (Note: Standard monograph for Procaine Hydrochloride would be consulted).

[4] Various Pharmaceutical Wholesaler Catalogs and Price Lists. (Ongoing Access). (Note: Access to current wholesale pricing data from entities like Cardinal Health, McKesson, or AmerisourceBergen is critical for market analysis).

[5] Global Market Research Reports on Local Anesthetics. (Various Publishers, Ongoing Access). (Note: While specific Novacaine market share is not always broken out, broader market data on local anesthetics is essential for context).